All In Biotech

Drug Trial Radar · NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,052 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,052

Actual

Start

Dec 6, 2007

Primary completion

Apr 30, 2019

Study completion Jan 1, 2028

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Nov 30, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.

Conditions

  • Clear Cell Adenocarcinoma
  • Fallopian Tube Clear Cell Adenocarcinoma
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube Mucinous Adenocarcinoma
  • Fallopian Tube Serous Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fallopian Tube Undifferentiated Carcinoma
  • Mucinous Adenocarcinoma
  • Ovarian Brenner Tumor
  • Ovarian Clear Cell Adenocarcinofibroma
  • Ovarian Clear Cell Adenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Ovarian Serous Adenocarcinoma
  • Ovarian Transitional Cell Carcinoma
  • Ovarian Undifferentiated Carcinoma
  • Primary Peritoneal Clear Cell Adenocarcinoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma
  • Primary Peritoneal Transitional Cell Carcinoma
  • Primary Peritoneal Undifferentiated Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Undifferentiated Carcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • CarboplatinDrug

    Given IV

  • DocetaxelDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Determine if Surgical Secondary Cytoreduction in Addition to Adjuvant Chemotherapy Increases the Duration of Overall Survival in Patients With Recurrent Platinum Sensitive Epithelial Ovarian Cancer, Peritoneal Primary or Fallopian Tube CancerTime frame: The time frame is 82.5 months (median duration of follow-up)
  2. To Determine if the Addition of Bevacizumab Increases the Duration of Overall Survival Relative to Second-line Paclitaxel and Carboplatin Alone in Patients With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Primary or Fallopian Tube CancerTime frame: The time frame is 82.5 months (median duration of follow-up).

Locations

709 sites in 3 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • John Muir Medical Center-Concord

    Concord, California

  • Sutter Davis Hospital

    Davis, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Long Beach Memorial Medical Center-Todd Cancer Institute

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • John Muir Medical Center-Walnut Creek

    Walnut Creek, California

  • Rocky Mountain Cancer Centers-Aurora

    Aurora, Colorado

Showing 40 of 709 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.